Alzheimer's Disease - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 1216
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1C4172E08CEN
Leaflet:

Download PDF Leaflet

Alzheimer's Disease - Pipeline Review, H2 2017
Alzheimer's Disease - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H2 2017, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 23, 49, 57, 2, 257, 94 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 111 and 47 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Alzheimer's Disease - Overview
Alzheimer's Disease - Therapeutics Development
Alzheimer's Disease - Therapeutics Assessment
Alzheimer's Disease - Companies Involved in Therapeutics Development
Alzheimer's Disease - Drug Profiles
Alzheimer's Disease - Dormant Projects 1105
Alzheimer's Disease - Discontinued Products 1135
Alzheimer's Disease - Product Development Milestones 1141
Appendix 1154

LIST OF TABLES

Number of Products under Development for Alzheimer's Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Products under Development by Companies, H2 2017 (Contd..18), H2 2017
Products under Development by Companies, H2 2017 (Contd..19), H2 2017
Products under Development by Companies, H2 2017 (Contd..20), H2 2017
Products under Development by Companies, H2 2017 (Contd..21), H2 2017
Products under Development by Companies, H2 2017 (Contd..22), H2 2017
Products under Development by Companies, H2 2017 (Contd..23), H2 2017
Products under Development by Companies, H2 2017 (Contd..24), H2 2017
Products under Development by Companies, H2 2017 (Contd..25), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..6), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Alzheimer's Disease - Pipeline by AB Science SA, H2 2017
Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2017
Alzheimer's Disease - Pipeline by AC Immune SA, H2 2017
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Accera Inc, H2 2017
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H2 2017
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2017
Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Affibody AB, H2 2017
Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2017
Alzheimer's Disease - Pipeline by Alector LLC, H2 2017
Alzheimer's Disease - Pipeline by Allergan Plc, H2 2017
Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Allinky Biopharma, H2 2017
Alzheimer's Disease - Pipeline by ALSP Inc, H2 2017
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2017
Alzheimer's Disease - Pipeline by Alzinova AB, H2 2017
Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2017
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Alzheimer's Disease - Pipeline by Amgen Inc, H2 2017
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H2 2017
Alzheimer's Disease - Pipeline by Annexon Inc, H2 2017
Alzheimer's Disease - Pipeline by Aphios Corp, H2 2017
Alzheimer's Disease - Pipeline by Apodemus AB, H2 2017
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H2 2017
Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Araclon Biotech SL, H2 2017
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by ArmaGen Inc, H2 2017
Alzheimer's Disease - Pipeline by Asceneuron SA, H2 2017
Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H2 2017
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2017
Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2017
Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H2 2017
Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Axxam SpA, H2 2017
Alzheimer's Disease - Pipeline by Beactica AB, H2 2017
Alzheimer's Disease - Pipeline by Berg LLC, H2 2017
Alzheimer's Disease - Pipeline by BioArctic AB, H2 2017
Alzheimer's Disease - Pipeline by Bioasis Technologies Inc, H2 2017
Alzheimer's Disease - Pipeline by Biogen Inc, H2 2017
Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H2 2017
Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H2 2017
Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2017
Alzheimer's Disease - Pipeline by Bsim2, H2 2017
Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Cardax Inc, H2 2017
Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Celon Pharma SA, H2 2017
Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Clera Inc, H2 2017
Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Cognosci Inc, H2 2017
Alzheimer's Disease - Pipeline by CohBar Inc, H2 2017
Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
Alzheimer's Disease - Pipeline by ConSynance Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Corium International Inc, H2 2017
Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H2 2017
Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc, H2 2017
Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H2 2017
Alzheimer's Disease - Pipeline by Daval International Ltd, H2 2017
Alzheimer's Disease - Pipeline by Denali Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H2 2017
Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Eisai Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Eli Lilly and Company, H2 2017
Alzheimer's Disease - Pipeline by Endece LLC, H2 2017
Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2017
Alzheimer's Disease - Pipeline by Ensol Biosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Epigen Biosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Evotec AG, H2 2017
Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Alzheimer's Disease - Pipeline by Genentech Inc, H2 2017
Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
Alzheimer's Disease - Pipeline by Genzyme Corp, H2 2017
Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H2 2017
Alzheimer's Disease - Pipeline by GliaCure Inc, H2 2017
Alzheimer's Disease - Pipeline by Glialogix Inc, H2 2017
Alzheimer's Disease - Pipeline by Golden Biotechnology Corp, H2 2017
Alzheimer's Disease - Pipeline by Grifols SA, H2 2017
Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2017
Alzheimer's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2017
Alzheimer's Disease - Pipeline by HitGen LTD, H2 2017
Alzheimer's Disease - Pipeline by ICB International Inc, H2 2017
Alzheimer's Disease - Pipeline by Ichor Medical Systems Inc, H2 2017
Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc, H2 2017
Alzheimer's Disease - Pipeline by Immungenetics AG, H2 2017
Alzheimer's Disease - Pipeline by Immunwork Inc, H2 2017
Alzheimer's Disease - Pipeline by Impel NeuroPharma Inc, H2 2017
Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by IntelGenx Corp, H2 2017
Alzheimer's Disease - Pipeline by Intellect Neurosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Intra-Cellular Therapies Inc, H2 2017
Alzheimer's Disease - Pipeline by Io Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Johnson & Johnson, H2 2017
Alzheimer's Disease - Pipeline by K-Stemcell Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Kadmon Corp LLC, H2 2017
Alzheimer's Disease - Pipeline by Karuna Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by KineMed Inc, H2 2017
Alzheimer's Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Lead Discovery Center GmbH, H2 2017
Alzheimer's Disease - Pipeline by Les Laboratoires Servier SAS, H2 2017
Alzheimer's Disease - Pipeline by Lipopharma Therapeutics SL, H2 2017
Alzheimer's Disease - Pipeline by Living Cell Technologies Ltd, H2 2017
Alzheimer's Disease - Pipeline by Lupin Ltd, H2 2017
Alzheimer's Disease - Pipeline by M3 Biotechnology Inc, H2 2017
Alzheimer's Disease - Pipeline by ManRos Therapeutics, H2 2017
Alzheimer's Disease - Pipeline by MedDay SA, H2 2017
Alzheimer's Disease - Pipeline by Medesis Pharma SA, H2 2017
Alzheimer's Disease - Pipeline by Medestea Research & Production SpA, H2 2017
Alzheimer's Disease - Pipeline by MedImmune LLC, H2 2017
Alzheimer's Disease - Pipeline by MEDRx Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by MEI Pharma Inc, H2 2017
Alzheimer's Disease - Pipeline by Merck & Co Inc, H2 2017
Alzheimer's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2017
Alzheimer's Disease - Pipeline by Microlin Bio Inc, H2 2017
Alzheimer's Disease - Pipeline by Mithridion Inc, H2 2017
Alzheimer's Disease - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Alzheimer's Disease - Pipeline by ModGene Pharma LLC, H2 2017
Alzheimer's Disease - Pipeline by Montisera Ltd, H2 2017
Alzheimer's Disease - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
Alzheimer's Disease - Pipeline by Nanomerics Ltd, H2 2017
Alzheimer's Disease - Pipeline by Nanotherapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by NeoNeuro SAS, H2 2017
Alzheimer's Disease - Pipeline by Neuralstem Inc, H2 2017
Alzheimer's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Alzheimer's Disease - Pipeline by Neuro-Sys SAS, H2 2017
Alzheimer's Disease - Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by NeuroNascent Inc, H2 2017
Alzheimer's Disease - Pipeline by NeurOp Inc, H2 2017
Alzheimer's Disease - Pipeline by Neuropore Therapies Inc, H2 2017
Alzheimer's Disease - Pipeline by Neurotez Inc, H2 2017
Alzheimer's Disease - Pipeline by New World Laboratories Inc, H2 2017
Alzheimer's Disease - Pipeline by nLife Therapeutics SL, H2 2017
Alzheimer's Disease - Pipeline by NoNO Inc, H2 2017
Alzheimer's Disease - Pipeline by Novartis AG, H2 2017
Alzheimer's Disease - Pipeline by Nymox Pharmaceutical Corp, H2 2017
Alzheimer's Disease - Pipeline by Orphit SAS, H2 2017
Alzheimer's Disease - Pipeline by Oryzon Genomics SA, H2 2017
Alzheimer's Disease - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Ovensa Inc, H2 2017
Alzheimer's Disease - Pipeline by P2D Bioscience, H2 2017
Alzheimer's Disease - Pipeline by Pain Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Peptron Inc, H2 2017
Alzheimer's Disease - Pipeline by Pfizer Inc, H2 2017
Alzheimer's Disease - Pipeline by PharmaKure Ltd, H2 2017
Alzheimer's Disease - Pipeline by Pharmaxis Ltd, H2 2017
Alzheimer's Disease - Pipeline by Pharnext SA, H2 2017
Alzheimer's Disease - Pipeline by Prevacus Inc, H2 2017
Alzheimer's Disease - Pipeline by Probiodrug AG, H2 2017
Alzheimer's Disease - Pipeline by Progenra Inc, H2 2017
Alzheimer's Disease - Pipeline by ProMIS Neurosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by ProQR Therapeutics NV, H2 2017
Alzheimer's Disease - Pipeline by Proteome Sciences Plc, H2 2017
Alzheimer's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by QR Pharma Inc, H2 2017
Alzheimer's Disease - Pipeline by Quimatryx SL, H2 2017
Alzheimer's Disease - Pipeline by Radius Health Inc, H2 2017
Alzheimer's Disease - Pipeline by Regenera Pharma Ltd, H2 2017
Alzheimer's Disease - Pipeline by reMYND NV, H2 2017
Alzheimer's Disease - Pipeline by Resverlogix Corp, H2 2017
Alzheimer's Disease - Pipeline by Rodos BioTarget GmbH, H2 2017
Alzheimer's Disease - Pipeline by Sage Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Samjin Pharm Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Samumed LLC, H2 2017
Alzheimer's Disease - Pipeline by SanBio Inc, H2 2017
Alzheimer's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Sangamo Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Sanofi, H2 2017
Alzheimer's Disease - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by SeneXta Therapeutics SA, H2 2017
Alzheimer's Disease - Pipeline by Serometrix LLC, H2 2017
Alzheimer's Disease - Pipeline by Shire Plc, H2 2017
Alzheimer's Disease - Pipeline by Signum Biosciences Inc, H2 2017
Alzheimer's Disease - Pipeline by Simcere Pharmaceutical Group, H2 2017
Alzheimer's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Alzheimer's Disease - Pipeline by Spherium Biomed SL, H2 2017
Alzheimer's Disease - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Summit Therapeutics Plc, H2 2017
Alzheimer's Disease - Pipeline by Suven Life Sciences Ltd, H2 2017
Alzheimer's Disease - Pipeline by T3D Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Alzheimer's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2017
Alzheimer's Disease - Pipeline by TechnoPhage SA, H2 2017
Alzheimer's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2017
Alzheimer's Disease - Pipeline by Telocyte LLC, H2 2017
Alzheimer's Disease - Pipeline by Tetra Discovery Partners LLC, H2 2017
Alzheimer's Disease - Pipeline by Therapix Biosciences Ltd, H2 2017
Alzheimer's Disease - Pipeline by Toyama Chemical Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Treventis Corp, H2 2017
Alzheimer's Disease - Pipeline by UCB SA, H2 2017
Alzheimer's Disease - Pipeline by Varinel Inc, H2 2017
Alzheimer's Disease - Pipeline by Virobay Inc, H2 2017
Alzheimer's Disease - Pipeline by VLP Therapeutics LLC, H2 2017
Alzheimer's Disease - Pipeline by Voyager Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by vTv Therapeutics Inc, H2 2017
Alzheimer's Disease - Pipeline by Vybion Inc, H2 2017
Alzheimer's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2017
Alzheimer's Disease - Pipeline by Xigen SA, H2 2017
Alzheimer's Disease - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017
Alzheimer's Disease - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..1), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..2), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..3), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..4), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..5), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..6), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..7), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..8), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..9), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..10), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..11), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..12), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..13), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..14), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..15), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..16), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..17), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..18), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..19), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..20), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..21), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..22), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..23), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..24), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..25), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..26), H2 2017
Alzheimer's Disease - Dormant Projects, H2 2017 (Contd..27), H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..1), H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..2), H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..3), H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..4), H2 2017
Alzheimer's Disease - Discontinued Products, H2 2017 (Contd..5), H2 2017

LIST OF FIGURES

Number of Products under Development for Alzheimer's Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AB Science SA
AbbVie Inc
AC Immune SA
Acadia Pharmaceuticals Inc
Accera Inc
Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Affibody AB
AFFiRiS AG
Alector LLC
Allergan Plc
Allgenesis Biotherapeutics Inc
Allinky Biopharma
ALSP Inc
Alzhyme Pty Ltd
Alzinova AB
AlzProtect SAS
Amarantus Bioscience Holdings Inc
Amgen Inc
Anavex Life Sciences Corp
Annexon Inc
Aphios Corp
Apodemus AB
Applied Research using OMIC Sciences SL
Aptevo Therapeutics Inc
Araclon Biotech SL
Archer Pharmaceuticals Inc
ArmaGen Inc
Asceneuron SA
Astellas Pharma Inc
AstraZeneca Plc
Aucta Pharmaceuticals LLC
Avineuro Pharmaceuticals Inc
Axon Neuroscience SE
Axovant Sciences Ltd
Axsome Therapeutics Inc
Axxam SpA
Beactica AB
Berg LLC
BioArctic AB
Bioasis Technologies Inc
Biogen Inc
BioHealthonomics Inc
Biomar Microbial Technologies
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Company
Bsim2
Cantabio Pharmaceuticals Inc
Cardax Inc
Carna Biosciences Inc
Celon Pharma SA
CHA Bio & Diostech Co Ltd
Clera Inc
Cognition Therapeutics Inc
Cognosci Inc
CohBar Inc
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
ContraVir Pharmaceuticals Inc
Corium International Inc
Coronis NeuroSciences Ltd
Cortice Biosciences Inc
Critical Outcome Technologies Inc
Crossbeta Biosciences BV
Daval International Ltd
Denali Therapeutics Inc
Domain Therapeutics SA
Dongkook Pharmaceutical Co Ltd
Eisai Co Ltd
Eli Lilly and Company
Endece LLC
Ensemble Therapeutics Corp
Ensol Biosciences Inc
Epigen Biosciences Inc
Evotec AG
F. Hoffmann-La Roche Ltd
Genentech Inc
Genervon Biopharmaceuticals LLC
Genzyme Corp
GlaxoSmithKline Plc
GliaCure Inc
Glialogix Inc
Golden Biotechnology Corp
Grifols SA
H. Lundbeck A/S
Heptares Therapeutics Ltd
HitGen LTD
ICB International Inc
Ichor Medical Systems Inc
Icure Pharmaceutical Inc
Immungenetics AG
Immunwork Inc
Impel NeuroPharma Inc
Inovio Pharmaceuticals Inc
IntelGenx Corp
Intellect Neurosciences Inc
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
K-Stemcell Co Ltd
Kadmon Corp LLC
Karuna Pharmaceuticals Inc
KineMed Inc
Krenitsky Pharmaceuticals Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lipopharma Therapeutics SL
Living Cell Technologies Ltd
Lupin Ltd
M3 Biotechnology Inc
ManRos Therapeutics
MedDay SA
Medesis Pharma SA
Medestea Research & Production SpA
MedImmune LLC
MEDRx Co Ltd
MEI Pharma Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
Microlin Bio Inc
Mithridion Inc
Mitsubishi Tanabe Pharma Corp
ModGene Pharma LLC
Montisera Ltd
NAL Pharmaceuticals Ltd
Nanomerics Ltd
Nanotherapeutics Inc
NeoNeuro SAS
Neuralstem Inc
Neuraltus Pharmaceuticals Inc
Neurim Pharmaceuticals Ltd
Neuro-Sys SAS
NeuroGenetic Pharmaceuticals Inc
NeuroNascent Inc
NeurOp Inc
Neuropore Therapies Inc
Neurotez Inc
New World Laboratories Inc
nLife Therapeutics SL
NoNO Inc
Novartis AG
Nymox Pharmaceutical Corp
Orphit SAS
Oryzon Genomics SA
Otsuka Holdings Co Ltd
Ovensa Inc
P2D Bioscience
Pain Therapeutics Inc
Panacea Pharmaceuticals Inc
Peptron Inc
Pfizer Inc
PharmaKure Ltd
Pharmaxis Ltd
Pharnext SA
Prevacus Inc
Probiodrug AG
Progenra Inc
ProMIS Neurosciences Inc
ProQR Therapeutics NV
Proteome Sciences Plc
Proteostasis Therapeutics Inc
QR Pharma Inc
Quimatryx SL
Radius Health Inc
Regenera Pharma Ltd
reMYND NV
Resverlogix Corp
Rodos BioTarget GmbH
Sage Therapeutics Inc
Samjin Pharm Co Ltd
Samumed LLC
SanBio Inc
Saneron CCEL Therapeutics Inc
Sangamo Therapeutics Inc
Sanofi
SBI Pharmaceuticals Co Ltd
SeneXta Therapeutics SA
Serometrix LLC
Shire Plc
Signum Biosciences Inc
Simcere Pharmaceutical Group
SK Biopharmaceuticals Co Ltd
Spectrum Pharmaceuticals Inc
Spherium Biomed SL
Sumitomo Dainippon Pharma Co Ltd
Summit Therapeutics Plc
Suven Life Sciences Ltd
T3D Therapeutics Inc
Takeda Pharmaceutical Company Ltd
TauRx Therapeutics Ltd
TechnoPhage SA
Teikoku Pharma USA Inc
Telocyte LLC
Tetra Discovery Partners LLC
Therapix Biosciences Ltd
Toyama Chemical Co Ltd
Treventis Corp
UCB SA
Varinel Inc
Virobay Inc
VLP Therapeutics LLC
Voyager Therapeutics Inc
vTv Therapeutics Inc
Vybion Inc
Wellstat Therapeutics Corp
Xigen SA
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Skip to top


Huntington's Disease - Pipeline Review, H2 2015 US$ 2,000.00 Nov, 2015 · 311 pages

Ask Your Question

Alzheimer's Disease - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: